 MONTREAL and CHARLOTTE, N.C., May 17, 2021 PRNewswire -- Milestone Pharmaceuticals Inc. Nasdaq: MIST, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals Ji Xing to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia PSVT and additional cardiovascular conditions in Greater China. 